External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
02 2021
Historique:
received: 17 05 2020
accepted: 19 09 2020
pubmed: 8 10 2020
medline: 18 9 2021
entrez: 7 10 2020
Statut: ppublish

Résumé

The nomogram reported by Gandaglia et al (The key combined value of multiparametric magnetic resonance imaging, and magnetic resonance imaging-targeted and concomitant systematic biopsies for the prediction of adverse pathological features in prostate cancer patients undergoing radical prostatectomy. Eur Urol 2020;77:733-41) predicting extracapsular extension (ECE) or seminal vesicle invasion (SVI) has been developed using multiparametric magnetic resonance imaging (MRI) parameters and MRI-targeted biopsy. We aimed to validate this nomogram externally by analyzing 566 patients harboring prostate cancer diagnosed on MRI-targeted biopsy followed by radical prostatectomy. At final pathology, 37% and 12% patients had ECE and SVI, respectively. Performance of the nomogram, in comparison with the Memorial Sloan Kettering Cancer Center (MSKCC) model and Partin tables, was evaluated using discrimination, calibration, and decision curve analysis. Regarding ECE prediction, the nomogram showed higher discrimination (71.8% vs 69.8%, p = 0.3 and 71.8% vs 61.3%, p < 0.001), and similar miscalibration and net benefit for probability threshold above 30% when compared with MSKCC model and Partin tables, respectively. Performance of the nomogram with regard to SVI was comparable in terms of discrimination (68.5% vs 70.4% vs 67.8%, p ≥ 0.6), presenting a slight overestimation on calibration plots and a net benefit for probability threshold above 7.5%. This is the first multicentric study that externally validates a nomogram predicting ECE and SVI in patients diagnosed with MRI-targeted biopsy. Its performance was less optimistic than expected, and implementation of MRI in this setting was not associated with a clear improvement in patient selection and clinical usefulness when compared with available models. We proposed an updated version of the nomogram predicting ECE using the recalibration method, which leads to an improvement in its performance and needs to be validated in another external set. PATIENT SUMMARY: We validate a prediction tool based on multiparametric magnetic resonance imaging (MRI) parameters and MRI-targeted biopsy predicting extracapsular extension and seminal vesicle invasion at radical prostatectomy. An improvement of patient selection was not clearly demonstrated when compared with available models based on clinical parameters, and implementation of MRI in this setting still needs to be clarified.

Identifiants

pubmed: 33023770
pii: S0302-2838(20)30764-8
doi: 10.1016/j.eururo.2020.09.037
pii:
doi:

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

180-185

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Romain Diamand (R)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: romain.diamand@erasme.ulb.ac.be.

Guillaume Ploussard (G)

Urology Department, La Croix du Sud Hospital, Quint Fonsegrives, France.

Mathieu Roumiguié (M)

Urology Department, CHU Toulouse, Toulouse, France.

Marco Oderda (M)

Urology Department, Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.

Daniel Benamran (D)

Urology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland.

Gaelle Fiard (G)

Urology Department, CHU de Grenoble, Grenoble, France; Grenoble Alpes University, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.

Thierry Quackels (T)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.

Grégoire Assenmacher (G)

Urology Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Giuseppe Simone (G)

Urology Department, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.

Julien Van Damme (J)

Urology Department, University Clinics Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

Bernard Malavaud (B)

Urology Department, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.

Christophe Iselin (C)

Urology Department, Hôpitaux Universitaires de Genève, Geneva, Switzerland.

Jean-Luc Descotes (JL)

Urology Department, CHU de Grenoble, Grenoble, France; Grenoble Alpes University, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.

Jean-Baptiste Roche (JB)

Urology Department, Clinique Saint-Augustin, Bordeaux, France.

Alexandre Peltier (A)

Urology Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Thierry Roumeguère (T)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium; Urology Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.

Simone Albisinni (S)

Urology Department, Hôpital Erasme, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH